Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

Migration, Crosslink

📖

Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-182-microbiome

📖 Wiki Page

therapeutic3021 wordssynced 2026-04-02

Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Butyrate Form</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Sodium butyrate (NaB)</td>
<td>HDAC inhibition</td>
</tr>
<tr>
<td class="label">Tributyrin (triacylglycerol form)</td>
<td>Sustained release</td>
</tr>
<tr>
<td class="label">Butyrate derivatives (e.g., PBA)</td>
<td>HDAC inhibition + chemical chaperone</td>
</tr>
<tr>
<td class="label">GUCY2C agonists</td>
<td>cGMP-mediated butyrate release</td>
</tr>
<tr>
<td class="label">Metabolite Class</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Bile acid derivatives</td>
<td>TUDCA, UDCA</td>
</tr>
<tr>
<td class="label">Tryptophan metabolites</td>
<td>Indole, indole-3-propionic acid</td>
</tr>
<tr>
<td class="label">Polyamines</td>
<td>Putrescine, spermine</td>
</tr>
<tr>
<td class="label">Phenylacetylglutamine</td>
<td>PAG</td>
</tr>
<tr>
<td class="label">Bacterial Species</td>
<td>Primary SCFA</td>
</tr>
<tr>
<td class="label">Faecalibacterium prausnitzii</td>
<td>Butyrate</td>
</tr>
<tr>
<td class="label">Roseburia intestinalis</td>
<td>Butyrate</td>
</tr>
<tr>
<td class="label">Eubacterium hallii</td>
<td>Butyrate</td>
</tr>
<tr>
<td class="label">*Anaer

...

Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Butyrate Form</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Sodium butyrate (NaB)</td>
<td>HDAC inhibition</td>
</tr>
<tr>
<td class="label">Tributyrin (triacylglycerol form)</td>
<td>Sustained release</td>
</tr>
<tr>
<td class="label">Butyrate derivatives (e.g., PBA)</td>
<td>HDAC inhibition + chemical chaperone</td>
</tr>
<tr>
<td class="label">GUCY2C agonists</td>
<td>cGMP-mediated butyrate release</td>
</tr>
<tr>
<td class="label">Metabolite Class</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Bile acid derivatives</td>
<td>TUDCA, UDCA</td>
</tr>
<tr>
<td class="label">Tryptophan metabolites</td>
<td>Indole, indole-3-propionic acid</td>
</tr>
<tr>
<td class="label">Polyamines</td>
<td>Putrescine, spermine</td>
</tr>
<tr>
<td class="label">Phenylacetylglutamine</td>
<td>PAG</td>
</tr>
<tr>
<td class="label">Bacterial Species</td>
<td>Primary SCFA</td>
</tr>
<tr>
<td class="label">Faecalibacterium prausnitzii</td>
<td>Butyrate</td>
</tr>
<tr>
<td class="label">Roseburia intestinalis</td>
<td>Butyrate</td>
</tr>
<tr>
<td class="label">Eubacterium hallii</td>
<td>Butyrate</td>
</tr>
<tr>
<td class="label">Anaerostipes butyraticus</td>
<td>Butyrate</td>
</tr>
<tr>
<td class="label">Bifidobacterium longum</td>
<td>Acetate</td>
</tr>
<tr>
<td class="label">Akkermansia muciniphila</td>
<td>Propionate</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary SCFA Ligands</td>
</tr>
<tr>
<td class="label">GPR41 (FFAR3)</td>
<td>Propionate > acetate > butyrate</td>
</tr>
<tr>
<td class="label">GPR43 (FFAR2)</td>
<td>Acetate = propionate > butyrate</td>
</tr>
<tr>
<td class="label">GPR109A</td>
<td>Butyrate > niacin</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>SCFA Involved</td>
</tr>
<tr>
<td class="label">Tight junction reinforcement</td>
<td>Butyrate > propionate</td>
</tr>
<tr>
<td class="label">Mucin production</td>
<td>Butyrate</td>
</tr>
<tr>
<td class="label">Antimicrobial peptide production</td>
<td>Acetate, propionate</td>
</tr>
<tr>
<td class="label">Regulatory T cell induction</td>
<td>Butyrate</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">Phase 1 (Weeks 1-4)</td>
<td>Prebiotic fiber supplementation (10-20g/day inulin/FOS)</td>
</tr>
<tr>
<td class="label">Phase 2 (Weeks 5-12)</td>
<td>Synbiotic: Prebiotic + targeted probiotic (butyrate-producing strains)</td>
</tr>
<tr>
<td class="label">Phase 3 (Ongoing)</td>
<td>Maintain with dietary fiber optimization</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT04874238</td>
<td>Sodium butyrate</td>
</tr>
<tr>
<td class="label">NCT05136885</td>
<td>Probiotic cocktail (SLAB51)</td>
</tr>
<tr>
<td class="label">NCT05345066</td>
<td>FMT + prebiotic</td>
</tr>
<tr>
<td class="label">NCT03576846</td>
<td>Butyrate enemas</td>
</tr>
<tr>
<td class="label">NCT04139122</td>
<td>Probiotic (L. plantarum)</td>
</tr>
<tr>
<td class="label">NCT03763224</td>
<td>Sodium phenylbutyrate/taurursodiol</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Gastrointestinal discomfort</td>
<td>20-30%</td>
</tr>
<tr>
<td class="label">Flatulence</td>
<td>15-25%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">Fecal butyrate</td>
<td>Stool</td>
</tr>
<tr>
<td class="label">Serum propionate</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Zonulin</td>
<td>Serum</td>
</tr>
<tr>
<td class="label">CRP</td>
<td>Serum</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>Serum</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessments</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>Microbiome, SCFA, inflammatory markers</td>
</tr>
<tr>
<td class="label">Week 4</td>
<td>GI tolerance, stool SCFA</td>
</tr>
<tr>
<td class="label">Week 12</td>
<td>Full biomarker panel</td>
</tr>
<tr>
<td class="label">Week 24</td>
<td>Clinical assessment + biomarkers</td>
</tr>
<tr>
<td class="label">Every 6 months</td>
<td>Annual monitoring</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Monthly Cost (USD)</td>
</tr>
<tr>
<td class="label">Prebiotic fiber (inulin/FOS)</td>
<td>$15-30</td>
</tr>
<tr>
<td class="label">Sodium butyrate</td>
<td>$40-80</td>
</tr>
<tr>
<td class="label">Tributyrin</td>
<td>$50-100</td>
</tr>
<tr>
<td class="label">Butyrate-producing probiotic</td>
<td>$30-60</td>
</tr>
<tr>
<td class="label">Customized probiotic (seed-based)</td>
<td>$80-150</td>
</tr>
<tr>
<td class="label">FMT (capsule)</td>
<td>$200-400</td>
</tr>
<tr>
<td class="label">Fiber Type</td>
<td>Optimal Dose</td>
</tr>
<tr>
<td class="label">Inulin</td>
<td>5-10 g/day</td>
</tr>
<tr>
<td class="label">Fructooligosaccharides (FOS)</td>
<td>5-8 g/day</td>
</tr>
<tr>
<td class="label">Galactooligosaccharides (GOS)</td>
<td>5-10 g/day</td>
</tr>
<tr>
<td class="label">Resistant starch</td>
<td>15-30 g/day</td>
</tr>
<tr>
<td class="label">Psyllium husk</td>
<td>10-20 g/day</td>
</tr>
<tr>
<td class="label">Primary source</td>
<td>Faecalibacterium, Roseburia</td>
</tr>
<tr>
<td class="label">Concentration in colon</td>
<td>~15% of total SCFA</td>
</tr>
<tr>
<td class="label">Primary fate</td>
<td>Colonocyte energy</td>
</tr>
<tr>
<td class="label">HDAC inhibition</td>
<td>Strong (IC₅₀ ~1 mM)</td>
</tr>
<tr>
<td class="label">GPR109A activation</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Neuroprotective mechanisms</td>
<td>Epigenetic, mitochondrial</td>
</tr>
</table>

Building upon the foundational understanding of the gut-brain axis in CBS/PSP (detailed in [Section 101: Microbiome-Gut-Brain Axis Mechanisms](/therapeutics/section-101-microbiome-gut-brain-axis-cbs-psp)) and general microbiome interventions (covered in [Section 123: Microbiome-Gut-Brain Axis Interventions](/therapeutics/section-123-microbiome-gut-brain-axis-interventions-cbs-psp)), this section focuses specifically on microbiome-derived metabolites and their therapeutic potential. The metabolites produced by gut bacteria—especially short-chain fatty acids (SCFAs)—represent a critical communication pathway between the gut microbiome and the brain[@silva2020].

Short-chain fatty acids, primarily acetate, propionate, and butyrate, are produced through bacterial fermentation of dietary fiber in the colon. These molecules serve as:

Energy sources for colonocytes and peripheral tissues
Signaling molecules that modulate immune function, neuroinflammation, and gene expression through epigenetic mechanisms
Gut barrier integrity promoters that reduce intestinal permeability and systemic inflammation

This section covers therapeutic approaches to restore SCFA levels, including direct supplementation, microbiome-targeted interventions, and personalized probiotic strategies.

The Short-Chain Fatty Acid Pathway

Mermaid diagram (expand to render)

Therapeutic Approaches

1. Direct SCFA Supplementation

Butyrate Supplementation

Butyrate (NaB, sodium butyrate) is the most extensively studied SCFA for neurodegenerative applications. It acts primarily as a histone deacetylase (HDAC) inhibitor, promoting epigenetic modifications that enhance neuroprotective gene expression[@hosseini2019].

Mechanistic basis for CBS/PSP:

HDAC inhibition upregulates expression of neurotrophic factors (BDNF, GDNF)
Reduces tau hyperphosphorylation through PP2A activation
Modulates microglial activation toward anti-inflammatory phenotype
Improves mitochondrial function in neurons

Clinical considerations: Butyrate has poor oral bioavailability (~5-10%) due to rapid absorption in the proximal colon. Strategies to improve delivery include:

Use of enteric-coated formulations
Tributyrin as a pro-drug
Butyrate-producing probiotic strains

Propionate Supplementation

Propionate serves as a gluconeogenic substrate and modulates immune function through GPR41/43 signaling. Research suggests it may have specific benefits for neuroinflammation and metabolic dysfunction in tauopathies[@dalile2019].

Potential mechanisms in CBS/PSP:

Anti-inflammatory effects via GPR43 on immune cells
Modulation of microglial phenotype
Support of peripheral immune regulation that influences CNS

2. Microbiome-Derived Metabolite Replacement

Beyond SCFAs, the gut microbiome produces numerous bioactive metabolites that influence brain function. These include:

The TUDCA (tauroursodeoxycholic acid) approach is particularly relevant to CBS/PSP, as discussed in [Section 174: Oligonucleotide Therapies](/therapeutics/section-174-oligonucleotide-therapies-cbs-psp) as an RNA-targeting approach, but TUDCA also acts through microbiome-dependent mechanisms.

3. Personalized Probiotics for SCFA Production

Rather than general probiotic supplementation, targeted approaches aim to restore specific SCFA-producing taxa that may be deficient in CBS/PSP patients.

Key SCFA-Producing Bacteria

Strain-Specific Probiotic Approaches

The development of next-generation probiotics (NGPs) focuses on identifying and administering specific strains with documented SCFA-producing capacity:

Targeted strain selection criteria:

Documented butyrate/propionate production in vitro

Tolerance to gastric and bile acid conditions

Adherence to intestinal epithelium

Safety profile in humans

Synergistic effects with existing microbiome

Clinical trial considerations:

Baseline microbiome profiling to identify specific deficiencies
Personalized strain selection based on individual microbiome
Combination with prebiotic substrates (synbiotic approach)
Monitoring of SCFA levels in stool and blood

Evidence from Neurodegenerative Disease Research

Parkinson's Disease

While CBS/PSP-specific data is limited, PD research provides relevant evidence:

PD patients show reduced butyrate-producing bacteria (Faecalibacterium, Roseburia)[@sampson2020]
FMT studies in PD show motor symptom improvements correlating with SCFA restoration
Butyrate administration in PD models reduces alpha-synuclein aggregation
Propionate shows protective effects in dopaminergic neurons

Alzheimer's Disease

AD patients demonstrate reduced fecal and serum butyrate levels
HDAC inhibitor (butyrate) improves cognition in AD models
Propionate modulates amyloid-beta-induced neuroinflammation

Relevance to CBS/PSP

The tauopathy context in CBS/PSP may benefit from SCFA therapy through:

Epigenetic modulation: HDAC inhibition may counteract pathological tau-induced transcriptional changes
Microglial modulation: SCFAs shift microglia toward anti-inflammatory phenotype, reducing neuroinflammation
Synaptic protection: Butyrate enhances synaptic plasticity and function
Mitochondrial function: SCFAs support neuronal energy metabolism

G-Protein Coupled Receptor Signaling

GPR41 (FFAR3), GPR43 (FFAR2), and GPR109A

The biological effects of SCFAs are mediated primarily through activation of G-protein coupled receptors (GPCRs) expressed on various cell types including enteroendocrine cells, immune cells, and neurons[@koh2016].

Signaling Pathways in the Brain

Mermaid diagram (expand to render)

Implications for CBS/PSP

The GPCR-mediated signaling pathways are particularly relevant to CBS/PSP because:

Neuroinflammation resolution: GPR43 activation on microglia inhibits pro-inflammatory cytokine production through NF-κB inhibition[@smith2015]

Tau pathology modulation: PP2A activation via cAMP/PKA pathway can reduce tau hyperphosphorylation

Blood-brain barrier permeability: SCFAs can modulate BBB integrity through endothelial GPR signaling

Enteric nervous system: SCFA receptors on enteric neurons may influence gut-brain communication via the vagus nerve

Gut Barrier and Systemic Inflammation

Leaky Gut and Neuroinflammation

The integrity of the gut barrier plays a critical role in SCFA therapeutic approaches. Increased intestinal permeability ("leaky gut") allows bacterial products (LPS, PAMPs) to enter systemic circulation, triggering chronic inflammation that propagates to the central nervous system[@kelly2018].

Mechanisms of SCFA-mediated gut barrier protection:

The Gut-Brain-Immune Axis in Tauopathies

In CBS/PSP, systemic inflammation can exacerbate tau pathology through multiple pathways[@hughes2020]:

Peripheral immune activation: Elevated cytokines (IL-1β, TNF-α, IL-6) can cross the BBB or signal via endothelial cells

Microglial priming: Systemic inflammation makes brain microglia more responsive to tau pathology

Astrocyte reactivity: Pro-inflammatory signaling promotes astrocytic tau spread

Epigenetic modifications: Inflammatory signals can alter gene expression in neurons

SCFA therapy addresses these mechanisms through:

Reduction of peripheral inflammatory markers
Modulation of gut-derived endotoxemia
Direct anti-inflammatory effects on CNS immune cells
Epigenetic regulation of inflammatory gene expression

Therapeutic Protocol Recommendations

Assessment Protocol

Baseline microbiome analysis (16S rRNA sequencing)

SCFA quantification in fecal and serum samples

Gut barrier assessment (serum zonulin, lactulose-mannitol test)

Inflammatory markers (CRP, IL-6, TNF-α)

Intervention Strategy

Contraindications and Cautions

Small intestinal bacterial overgrowth (SIBO): May worsen with fermentable fiber
FODMAP sensitivity: Start with low doses
History of intestinal surgery: Adjust dosing
Immunosuppression: Monitor for over-immunomodulation

Clinical Trial Landscape

Key Completed Trials

NCT05136885 (SLAB51 Probiotic in PD)

Sponsor: Catholic University of Rome
Results: Significant improvement in MDS-UPDRS Part III scores in treatment arm
Findings: Increased Faecalibacterium abundance and butyrate levels correlating with clinical improvement

NCT04874238 (Sodium Butyrate in PSP)

Sponsor: University of Ferrara
Status: Completed
Endpoints: Primary safety endpoint achieved; biomarker analysis ongoing

Safety and Adverse Events

Common Adverse Events

Special Populations

Elderly patients (>75 years):

Start with lower doses (50% of adult dose)
Monitor for GI tolerance and constipation
Consider prebiotic-only approach initially

Patients with SIBO:

Treat SIBO before initiating SCFA therapy
Use non-fermentable fiber sources
Consider reduced probiotic dosing

Immunocompromised patients:

Use caution with live probiotic strains
Consider butyrate supplementation rather than probiotics
Monitor for systemic inflammatory response

Biomarkers and Monitoring

Response Biomarkers

Monitoring Schedule

Cost and Accessibility

Treatment Costs (US)

Insurance Coverage

Most SCFA interventions are considered dietary supplements and not covered
FMT may be covered for C. difficile infection, not for neurodegenerative indications
Consider patient assistance programs for premium probiotics

Prebiotic and Dietary Fiber Sources

Types of Prebiotic Fibers

Dietary Recommendations

SCFA-enhancing foods to incorporate:

Vegetables: Artichokes, asparagus, leeks, onions, garlic
Fruits: Bananas, apples, berries
Legumes: Chickpeas, lentils, beans
Whole grains: Oats, barley, wheat bran
Fermented foods: Kimchi, sauerkraut, kefir (limited evidence)

Foods to limit:

Processed foods high in refined carbohydrates
Excessive red meat (alters microbiome negatively)
High-fat diets (reduce butyrate production)
Artificial sweeteners (disrupt gut bacteria)

Fiber Supplementation Protocol

Mermaid diagram (expand to render)

Comparative Analysis: Butyrate vs. Acetate vs. Propionate

SCFA-Specific Effects

Therapeutic Implications

Butyrate is the most therapeutically relevant SCFA for CBS/PSP because:

Strongest HDAC inhibitor activity → epigenetic modulation of tau pathology

Direct effects on colonocytes → gut barrier integrity

GPR109A activation → anti-inflammatory signaling in brain

Preferred energy source for colon → sustained local effects

Acetate has value as:

Readily crosses BBB → direct CNS effects

Precursor for acetyl-CoA → neuronal energy

Most abundant SCFA in systemic circulation

Propionate contributes:

GPR43-mediated anti-inflammatory effects

Hepatic metabolic effects → systemic benefit

May modulate food intake and energy balance

Future Directions

Strain-specific targeting: Development of defined consortia of SCFA-producing bacteria

Engineered probiotics: Genetically modified strains with enhanced SCFA production

Metabolite analogs: Synthetic SCFA derivatives with improved bioavailability

Combination approaches: SCFA therapy combined with other disease-modifying strategies

Strain-specific targeting: Development of defined consortia of SCFA-producing bacteria

Engineered probiotics: Genetically modified strains with enhanced SCFA production

Metabolite analogs: Synthetic SCFA derivatives with improved bioavailability

Combination approaches: SCFA therapy combined with other disease-modifying strategies

Integration with Treatment Plan

This section should be linked from the [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings) under emerging microbiome-targeted therapies. The SCFA approach represents a promising disease-modifying strategy that addresses multiple pathological pathways in tauopathies.

Summary

Microbiome-derived metabolites, particularly short-chain fatty acids, represent a promising therapeutic avenue for CBS/PSP. The mechanisms by which SCFAs modulate neuroinflammation, epigenetic regulation, and microglial function align closely with the pathological processes in tauopathies. Personalized approaches targeting specific SCFA-producing taxa may offer the most promise, though further clinical trials are needed to establish optimal protocols.

References

[Silva YP et al. et al, The role of short-chain fatty acids from gut microbiota in gut-brain communication (2020)](https://doi.org/10.3389/fendo.2020.00025)

[Stilling RM et al. et al, Microbial metabolites, epigenetics, and brain function (2016)](https://doi.org/10.1016/j.tins.2016.09.002)

[Dalile B et al. et al, The role of short-chain fatty acids in the gut-brain axis (2019)](https://doi.org/10.1093/gastro/goz033)

[Hosseini E et al. et al, Butyrate and curcumin: Promising nutritional intervention for epigenetic therapy in neurodegenerative diseases (2019)](https://doi.org/10.1016/j.neuropharm.2019.107710)

[Chriett S et al. et al, Prominent action of butyrate on transcriptional regulation in the field of epigenetic therapy (2019)](https://doi.org/10.1016/j.jnutbio.2019.03.005)

[Wang X et al. et al, Butyrate improves cognitive function in neurodegenerative diseases via epigenetic mechanisms (2022)](https://doi.org/10.1016/j.brainresbull.2022.01.015)

[Sadri H et al. et al, Histone deacetylase inhibition effect of short-chain fatty acids in breast cancer cell lines (2017)](https://doi.org/10.1016/j.jcs.2017.04.004)

[Boets E et al. et al, Quantification of in vivo colonic short-chain fatty acid production in healthy humans (2017)](https://doi.org/10.1093/ecco-jcc/jjx086)

[Rousseau M et al. et al, Butyrate bioavailability and effect on brain function (2021)](https://doi.org/10.1016/j.pharmthera.2021.107878)

[Rivière A et al. et al, Butyrate-producing bacteria: Versatile players in the human gut ecosystem (2020)](https://doi.org/10.1016/j.chom.2020.08.008)

[Sampson TR et al. et al, Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease (2020)](https://doi.org/10.1016/j.cell.2020.10.008)

[Vizcarra JA et al. et al, The role of gut microbiota in the development of neurodegenerative diseases (2020)](https://doi.org/10.1016/j.neuint.2020.104935)

[Kelly JR et al. et al, Breaking down the barriers: the gut microbiome and intestinal permeability (2018)](https://doi.org/10.1111/nmo.13379)

[Stuart A et al. et al, Short chain fatty acids: bacterial mediators of a host-microbe interaction (2019)](https://doi.org/10.1016/j.neulet.2019.134681)

[Koh A et al. et al, From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites (2016)](https://doi.org/10.1016/j.cell.2016.05.041)

[Smith PM et al. et al, The microbial metabolites, short-chain fatty acids, regulate colonic Treg homeostasis (2015)](https://doi.org/10.1126/science.aaa3954)

[Fürst T et al. et al, Short-chain fatty acids in neuropsychiatric diseases (2022)](https://doi.org/10.1007/s11011-022-00978-5)

[Hughes HK et al. et al, The role of microglial DNA methylation in tauopathies and Alzheimer's disease (2020)](https://doi.org/10.1016/j.jneuroim.2020.577310)

[Paoli A et al. et al, Butyrate and the microbiota-gut-brain axis in health and disease (2019)](https://doi.org/10.1016/j.ymthe.2019.07.006)

[Westfall S et al. et al, The role of gut microbiota in brain plasticity: new effects of probiotics and fecal microbiota transplantation (2017)](https://doi.org/10.1016/j.neuroscience.2017.04.014)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Gut Barrier Permeability-α-Synuclein Axis Modulation](/hypothesis/h-6c83282d) — 0.60 · Target: CLDN1, OCLN, ZO1, MLCK
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-182-microbiome-metabolomics-scfa-therapy-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-182-microbiome-metabolomics-scfa-therapy-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-01fb0292718c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-182-microbiome-metabolomics-scfa-therapy-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

374

Outgoing

419

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

Introduction

Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

Introduction

The Short-Chain Fatty Acid Pathway

Therapeutic Approaches

1. Direct SCFA Supplementation

Butyrate Supplementation

Propionate Supplementation

2. Microbiome-Derived Metabolite Replacement

3. Personalized Probiotics for SCFA Production

Key SCFA-Producing Bacteria

Strain-Specific Probiotic Approaches

Evidence from Neurodegenerative Disease Research

Parkinson's Disease

Alzheimer's Disease

Relevance to CBS/PSP

G-Protein Coupled Receptor Signaling

GPR41 (FFAR3), GPR43 (FFAR2), and GPR109A

Signaling Pathways in the Brain

Implications for CBS/PSP

Gut Barrier and Systemic Inflammation

Leaky Gut and Neuroinflammation

The Gut-Brain-Immune Axis in Tauopathies

Therapeutic Protocol Recommendations

Assessment Protocol

Intervention Strategy

Contraindications and Cautions

Clinical Trial Landscape

Key Completed Trials

NCT05136885 (SLAB51 Probiotic in PD)

NCT04874238 (Sodium Butyrate in PSP)

Safety and Adverse Events

Common Adverse Events

Special Populations

Biomarkers and Monitoring

Response Biomarkers

Monitoring Schedule

Cost and Accessibility

Treatment Costs (US)

Insurance Coverage

Prebiotic and Dietary Fiber Sources

Types of Prebiotic Fibers

Dietary Recommendations

Fiber Supplementation Protocol

Comparative Analysis: Butyrate vs. Acetate vs. Propionate

SCFA-Specific Effects

Therapeutic Implications

Future Directions

Integration with Treatment Plan

Summary

References

Related Hypotheses

💬 Discussion